Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Up 5.8% in December

Structure Therapeutics Inc. (NASDAQ:GPCR) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 10,750,000 shares, an increase of 5.8% from the December 15th total of 10,160,000 shares. Based on an average daily volume of 824,600 shares, the short-interest ratio is presently 13.0 days. Approximately 19.8% of the company’s shares are sold short.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $27.06 on Tuesday. The stock has a fifty day simple moving average of $30.78 and a two-hundred day simple moving average of $36.03. Structure Therapeutics has a 52-week low of $23.50 and a 52-week high of $62.74. The firm has a market capitalization of $1.55 billion, a PE ratio of -36.57 and a beta of -2.78.

Institutional Trading of Structure Therapeutics

Several hedge funds have recently made changes to their positions in the business. Janney Capital Management LLC lifted its stake in Structure Therapeutics by 36.4% in the fourth quarter. Janney Capital Management LLC now owns 9,007 shares of the company’s stock worth $244,000 after purchasing an additional 2,405 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in Structure Therapeutics in the fourth quarter worth about $40,000. GAMMA Investing LLC boosted its stake in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after purchasing an additional 1,122 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Structure Therapeutics by 302.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company’s stock valued at $1,489,000 after acquiring an additional 25,500 shares during the period. Finally, Principal Financial Group Inc. grew its stake in Structure Therapeutics by 230.0% in the third quarter. Principal Financial Group Inc. now owns 545,359 shares of the company’s stock valued at $23,936,000 after purchasing an additional 380,115 shares during the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on GPCR shares. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective for the company. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, Morgan Stanley assumed coverage on Structure Therapeutics in a research note on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $81.29.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.